Topics covered in this report
Outlook for combination antibody therapeutics
Introduction, Scope and Objectives
A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
Ipilimumab: Immune checkpoint inhibitors
Opportunities and challenges for future development
1.2.1. A need for targets.
Objectives and outlook for combination antibody therapy
1.3.1. Overcoming resistance to anti-cancer agents.
1.3.2. Uncertainties in combined antibody therapy.
Targeted Antibody Therapeutics
2.1. The unstable cancer genome.
2.2. The epigenome.
2.3. Chemotherapy treatment combined with antibodies
2.4. Combinations of targeted antibodies
2.5. Targeted antibody therapeutics and the marketplace
2.6. Targeted antibody therapeutics in the clinic
Development and Current Products
Combination of Chemotherapy and Immuno-antibody therapeutics
Combinations of immune-antibodies
Immuno- antibody therapeutics in the marketplace
3.5. Immuno- antibody therapeutics in the clinic
Fusion Antibody Therapeutics
4.1. Antibody Drug Conjugates (ADCs)
Antibody Biologic Constructs (ABCs)
Fusion antibodies in combination with other drugs
Multitargeted and Polyfunctional Antibody Therapeutics
5.1. Status and clinical studies of Bispecific and bi-targeted antibodies
5.2. Recombinant polyclonal antibodies
5.3. Combination therapy
5.4. Challenges in manufacturing
5.5. Regulatory areas: Challenges
Patent Expiration and the Rise of Biosimilars
Biosimilar antibodies in the market
Target products nearing patent expiration
Prospects for biobetters
A bright future for modified antibodies
Deals and the Marketplace
7.1. Mergers and acquisitions
7.3. The Mother of all Mergers
8.1. Balancing basic and clinical research
8.1.1. A troubled time for the life sciences
8.1.2. Shoddy and questionable research
8.1.3. A resolution to the funding crisis?
8.1.4. Promising areas of discovery in cancer combination therapies
22.214.171.124. Rectal cancer therapies
New approaches to oncology: Diagnostics versus therapeutics
8.2.1. The frustrating search for effective disease biomarkers
8.2.2. A mix of approaches to cancer biomarker discovery.
8.2.3. Three approaches to immunodiagnostic cancer markers
126.96.36.199. The first is the traditional approach of characterization of a single cancer-related marker and its validation as an immunodiagnostic test.
188.8.131.52. The second approach has evolved as sophisticated instrumentation for multiplexing has become more widely available.
184.108.40.206. Yet a third approach is a more indirect one – identifying tumor-specific antibodies in the serum of affected individuals.
8.2.4. Current cancer markers in use
8.3. Opportunities and pitfalls
8.3.1. NCI-MATCH trials
8.3.2. A wide range of treatments offers better odds of survival.
Interviews with Experts in the Field
9.1. Interview with Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
9.2. Interview with Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
9.3. Interview with Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
9.4. Interview with Dr. Cheng Liu, CEO, Eureka Therapeutics
9.5. Interview with Steve King, President, Peregrine Pharma
Questionnaire put to Industry Representatives Concerning Developments in Antibody Technology
About Cambridge Healthtech Institute
Figure 220.127.116.11. Timeline for development of ipilimumab.
Figure 18.104.22.168. Binding sites on human epidermal growth factor receptor 2 (HER2) for FDA-approved HER2-directed therapies
Figure 2.1. Mechanisms that drive drug resistance in cancer cells
Figure 2.2.1. Depiction of the Primary Mechanisms that Enable Cancer Cells to Become Drug Resistant
Figure 3.1.1. Flash Gordon Comic Strip from the 1950s.
Figure 3.1. The Il-2 pathway.
Figure 3.2.1. MAPK Pathway and Mechanism of Vemurafenib
Figure 3.3.1. Domain Architecture and Affinity Purification of a scFv:CD40L Fusion Proteins
Figure 5.1.1. Alternative possibilities for bispecific Antibodies.
Figure 22.214.171.124. Biomarker discovery over the last 30 years
Figure 8.4.1. Rate of new drug approvals.
Table 1.1. FDA-Approved Epigenetic Therapies
Table 3.1.1. Currently Approved Non-mAb Anticancer Immunotherapeutics.
Table 4.1.1. Seattle Genetics ADCs in clinical trials
Table 5.2.1. Examples of Oligoclonal and polyclonal antibody therapeutics in development.
Table 6.XX: Needs a Title
Table 7.1: Merger and Acquisition Trends